Physician profile
Linna Li
NPI 1699929844
$15,576.68
in general payments reported to CMS, 2019-2025
30 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $350 · 2021: $2,156 · 2022: $515 · 2023: $2,047 · 2024: $7,973 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,650 · Travel and Lodging: $2,682 · Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,650.00 |
| Travel and Lodging | $2,682.01 |
| Food and Beverage | $1,536.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $7,650.00 | 2024 | |
| Reflexion Medical, INC. | $2,168.40 | 2022-2023 | Reflexion Medical Radiotherapy System |
| Davol INC. | $2,000.00 | 2021 | |
| Siemens Medical Solutions USA, INC. | $1,861.64 | 2024-2025 | Varian Ethos Treatment Planning |
| Astrazeneca Pharmaceuticals LP | $361.98 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Novocure INC. | $163.27 | 2021-2025 | Optune, Optune Gio |
| Celgene Corporation | $143.90 | 2019 | |
| Seagen INC. | $141.87 | 2019-2023 | Adcetris |
| Janssen Biotech, INC. | $131.83 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2020 | |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.80 | 2022 | |
| Eisai INC. | $86.75 | 2019-2023 | |
| Lilly USA, LLC | $61.30 | 2019-2023 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $44.02 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $42.39 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $42.01 | 2025 | Enhertu |
| Fortovia Therapeutics, INC. | $36.80 | 2019 | |
| Puma Biotechnology, INC. | $36.25 | 2019 | |
| Genmab U.S., INC. | $33.06 | 2024 | Epkinly |
| Morphosys, US INC. | $31.35 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $30.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.60 | 2024 | Libtayo |
| Accuray Incorporated | $22.17 | 2024 | |
| Pfizer INC. | $21.46 | 2024 | |
| Astellas Pharma US INC | $20.49 | 2025 | Padcev |
| Incyte Corporation | $20.03 | 2023 | Jakafi |
| Ambu INC. | $18.17 | 2025 | |
| Clovis Oncology, INC. | $15.55 | 2019 | |
| Exelixis INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linna Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.